Zebra Technologies reported strong financial results for the third quarter of 2024, with net sales reaching $1,255 million, marking a 31.3% year-over-year increase. The company also posted a net income of $137 million, translating to a net income per diluted share of $2.64. Additionally, its non-GAAP diluted earnings per share rose to $3.49, and adjusted EBITDA improved to $268 million. Following these results, Zebra raised its full-year free cash flow guidance, reflecting ongoing demand and positive performance in the market. The company's stock saw a pre-market increase of 7.5% as investors reacted to the earnings announcement. Other companies, including AtriCure, CVRx, and Neurocrine Biosciences, also reported their third-quarter results on the same day, with Neurocrine raising its sales guidance for INGREZZA.